DE1795438C2 - S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053 - Google Patents

S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053

Info

Publication number
DE1795438C2
DE1795438C2 DE1795438A DE1795438DA DE1795438C2 DE 1795438 C2 DE1795438 C2 DE 1795438C2 DE 1795438 A DE1795438 A DE 1795438A DE 1795438D A DE1795438D A DE 1795438DA DE 1795438 C2 DE1795438 C2 DE 1795438C2
Authority
DE
Germany
Prior art keywords
diamino
acid methyl
preparation
carboxylic acid
methyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE1795438A
Other languages
German (de)
English (en)
Other versions
DE1795438B1 (de
Inventor
Edward Jethro Lansdale R.D. Pa. Cragoejun. (V.St.A.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE1795438B1 publication Critical patent/DE1795438B1/de
Application granted granted Critical
Publication of DE1795438C2 publication Critical patent/DE1795438C2/de
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE1795438A 1962-10-30 1963-10-28 S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053 Expired DE1795438C2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23423062A 1962-10-30 1962-10-30
US313315A US3313813A (en) 1962-10-30 1963-10-07 (3-amino-5, 6-disubstituted-pyrazinoyl) guanidines

Publications (2)

Publication Number Publication Date
DE1795438B1 DE1795438B1 (de) 1973-09-06
DE1795438C2 true DE1795438C2 (de) 1974-04-11

Family

ID=26927694

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19631470053 Pending DE1470053A1 (de) 1962-10-30 1963-10-28 5,6-disubstituierte (3-Aminopyrazinoyl)-guanidinverbindungen und Verfahren zu deren Herstellung
DE1795438A Expired DE1795438C2 (de) 1962-10-30 1963-10-28 S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19631470053 Pending DE1470053A1 (de) 1962-10-30 1963-10-28 5,6-disubstituierte (3-Aminopyrazinoyl)-guanidinverbindungen und Verfahren zu deren Herstellung

Country Status (13)

Country Link
US (1) US3313813A (cs)
BE (1) BE639386A (cs)
BR (1) BR6354164D0 (cs)
CH (1) CH465617A (cs)
CY (1) CY440A (cs)
DE (2) DE1470053A1 (cs)
DK (4) DK114978B (cs)
FI (1) FI47102C (cs)
FR (1) FR1563612A (cs)
GB (1) GB1066855A (cs)
MY (1) MY6900026A (cs)
NL (2) NL142413B (cs)
SE (1) SE321230B (cs)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6409714A (cs) * 1962-10-30 1965-10-01
US3472848A (en) * 1966-11-17 1969-10-14 Merck & Co Inc 3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
US3948895A (en) * 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4087526A (en) * 1976-07-23 1978-05-02 Merck & Co., Inc. (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
US4208413A (en) * 1977-03-04 1980-06-17 Merck & Co., Inc. N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
US4108859A (en) * 1977-06-06 1978-08-22 The Dow Chemical Company Microbicidal (pyridinylamino) alkyl guanidines
US4140776A (en) * 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
US4190655A (en) * 1978-08-28 1980-02-26 Merck & Co., Inc. Amiloride citrate
EP0009054A1 (en) * 1978-09-19 1980-04-02 Merck & Co. Inc. N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same
US4246406A (en) * 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4224447A (en) * 1979-03-27 1980-09-23 Merck & Co., Inc. Novel pyrazinecarboxamides and processes for preparing same
US4362724A (en) * 1980-05-19 1982-12-07 Merck & Co., Inc. Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
US4309540A (en) * 1980-05-19 1982-01-05 Merck & Co., Inc. Substituted pyrazinyl-1,2,4-oxadiazoles
US4454132A (en) * 1981-03-16 1984-06-12 Merck & Co., Inc. Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4952582A (en) * 1982-01-04 1990-08-28 Beyer Jr Karl H Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
US4663322A (en) * 1982-01-04 1987-05-05 Beyer Jr Karl H Antihypertensive hyperuretic and saluretic agent combinations
DE3312516A1 (de) * 1983-04-07 1984-10-11 Brigitte Dr. 7400 Tübingen Pfeiffer Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
DE3925847A1 (de) * 1989-08-04 1991-02-07 Huels Chemische Werke Ag Verfahren zur herstellung von 3-aminopyrazin-2-carbonsaeuremethylester
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
AU654979B2 (en) * 1990-10-05 1994-12-01 University Of North Carolina At Chapel Hill, The Method of administering amiloride
TW213903B (cs) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5801177A (en) * 1995-12-14 1998-09-01 Beyer, Jr.; Karl H. Method for controlling and/or lowering serum glucose and fatty acid concentrations and hypertensive blood pressure in non-insulin-dependent diabetic patients
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
AU9124998A (en) * 1997-08-29 1999-03-16 Inspire Pharmaceuticals Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung iseases
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
CA2360687A1 (en) * 1999-01-29 2000-08-03 Karl H. Beyer, Jr. (Deceased) Composition and method for treating diabetes
PT1196396E (pt) 1999-07-19 2008-05-14 Univ North Carolina Compostos farmacologicamente activos com dois princípios activos covalentemente ligados (bloqueador dos canais do sódio/agonista do receptor p2y2) para o tratamento de superfícies mucosas
DE60119368T2 (de) 2000-11-21 2007-05-03 Sankyo Co., Ltd. Zusammensetzung enthaltend einen angiotensin-ii-rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003234464B2 (en) * 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
AU2004248859C1 (en) * 2003-06-26 2011-11-24 Biotron Limited Antiviral acylguanidine compounds and methods
NZ544671A (en) 2003-06-26 2009-02-28 Biotron Ltd Antiviral compounds and methods
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
EP1663235B1 (en) 2003-08-18 2013-07-24 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
JP2007502827A (ja) * 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CA2630920A1 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
TWI432198B (zh) 2008-02-26 2014-04-01 Parion Sciences Inc 多芳香族鈉通道阻斷劑
DE102008053024B4 (de) 2008-10-24 2015-04-30 RUHR-UNIVERSITäT BOCHUM Verwendung von Amilorid-Derivaten zur Bekämpfung von Insekten und Milben
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
KR102109223B1 (ko) 2012-05-29 2020-05-11 패리온 사이언스 인코퍼레이티드 안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
CA2909442A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2015003958A1 (en) * 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP6927042B2 (ja) * 2016-07-29 2021-08-25 東レ株式会社 グアニジン誘導体及びその医薬用途
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299929A (cs) * 1962-10-30

Also Published As

Publication number Publication date
NL142413B (nl) 1974-06-17
BR6354164D0 (pt) 1973-09-18
DK114557B (da) 1969-07-14
SE321230B (cs) 1970-03-02
CY440A (en) 1968-05-18
DE1470053A1 (de) 1969-06-26
CH465617A (de) 1968-11-30
DE1795438B1 (de) 1973-09-06
FI47102C (fi) 1973-09-10
US3313813A (en) 1967-04-11
BE639386A (cs)
MY6900026A (en) 1969-12-31
DK116943B (da) 1970-03-02
NL299931A (cs)
GB1066855A (en) 1967-04-26
FR1563612A (cs) 1969-04-18
DK114978B (da) 1969-08-25
FI47102B (cs) 1973-05-31
DK115403B (da) 1969-10-06

Similar Documents

Publication Publication Date Title
DE1795438C2 (de) S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053
DE2257711B2 (de) Verfahren zur Herstellung von mit einem Benzol-, Naphthalin- oder Pyridinring kondensierten Bis-(3-[indolyl] -furan-(2)-onen
CH640224A5 (de) 2-pyrrolidonderivate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von 4-aminohex-5-ensaeure.
CH597199A5 (en) 3-Phenyl pyridaz-6-ones prodn.
DE2064096C3 (de) Verfahren zur Herstellung von in 6-Stellmtg substituierten 2,4-Dichlorpyrimidin-S-carbonsSureestern
DE2737481A1 (de) Verfahren zur herstellung von 2-alkyl- oder 2-cycloalkyl-4-methyl-6-hydroxypyrimidinen
DE4408083C1 (de) Verfahren zur Herstellung von 4-Fluoralkoxyzimtsäurenitrilen
DE1770976A1 (de) Isothiazolderivate und ein Verfahren zu ihrer Herstellung
AT339482B (de) Verfahren zur herstellung neuer organischer amid-verbindungen
DE2625163A1 (de) Alpha-chlorcarbonsaeuren und verfahren zu ihrer herstellung
WO1998043958A1 (de) Verfahren zur herstellung von 2,6-dichlor-5-fluornicotinonitril und die chemische verbindung 3-cyano-2-hydroxy-5-fluorpyrid-6-on-mononatriumsalz sowie dessen tautomere
AT364836B (de) Verfahren zur herstellung von neuen o-substituierten derivaten des (+)-cyanidan-3-ols und deren salzen
EP0073871B1 (de) Verfahren zur Herstellung von N-substituierten N-Acetyl-2,6-dialkylanilinen
AT210425B (de) Verfahren zur Herstellung von neuen Benzo-1, 3-thiazindionen-(2, 4)
AT258916B (de) Verfahren zur Herstellung von neuen Alkyl-3-amino-5-chlor-6-X-pyrazinoaten
AT162937B (de) Verfahren zur Herstellung eines neuen substituierten 2,4-Diamino-1,3,5-triazins
AT228205B (de) Verfahren zur Herstellung von basischen Phenothiazin-Derivaten, die in 3-Stellung mit einer einwertigen Schwefelfunktion substituiert sind
AT373588B (de) Verfahren zur herstellung von neuen substituierten 1-benzoyl-2-phenylimino-imidazolidinen und von deren salzen
AT273144B (de) Verfahren zur Herstellung von neuen Benzoxadiazocin-Derivaten
AT243808B (de) Verfahren zur Herstellung von neuen 5,6-Dihydro-6-oxo-11 H-pyrido-[2,3-b][1,4]-benzodiazepinen
AT216504B (de) Verfahren zur Herstellung von neuen Isoindolinderivaten
AT230357B (de) Verfahren zur Herstellung von neuen Benzoesäurederivaten
AT204048B (de) Verfahren zur Herstellung von neuen Phenazinderivaten
AT266140B (de) Verfahren zur Herstellung von neuen Pyrazinverbindungen
AT227713B (de) Verfahren zur Herstellung von neuen 1,5-Diazacyclooctan-Derivaten

Legal Events

Date Code Title Description
E77 Valid patent as to the heymanns-index 1977